Cumberland Pharmaceuticals Inc.

NasdaqGS:CPIX Stock Report

Market Cap: US$31.9m

Cumberland Pharmaceuticals Management

Management criteria checks 3/4

Cumberland Pharmaceuticals' CEO is A. Kazimi, appointed in Jan 1999, has a tenure of 25.92 years. total yearly compensation is $1.17M, comprised of 57.7% salary and 42.3% bonuses, including company stock and options. directly owns 40.6% of the company’s shares, worth $12.94M. The average tenure of the management team and the board of directors is 7 years and 11.6 years respectively.

Key information

A. Kazimi

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage57.7%
CEO tenure25.9yrs
CEO ownership40.6%
Management average tenure7yrs
Board average tenure11.6yrs

Recent management updates

Recent updates

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Nov 04
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Mar 07
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

Jan 09
Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Oct 02
Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Aug 10
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?

Mar 18
Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Nov 02
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)

Jul 20
Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Apr 15
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Checking In On Cumberland Pharmaceuticals

Jan 04

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Nov 09
Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Apr 21
We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

Feb 13
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Nov 19
One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Cumberland Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

CEO Compensation Analysis

How has A. Kazimi's remuneration changed compared to Cumberland Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$11m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$1mUS$675k

-US$6m

Sep 30 2023n/an/a

-US$2m

Jun 30 2023n/an/a

-US$2m

Mar 31 2023n/an/a

-US$4m

Dec 31 2022US$1mUS$635k

-US$6m

Sep 30 2022n/an/a

-US$7m

Jun 30 2022n/an/a

-US$9m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$1mUS$610k

-US$6m

Sep 30 2021n/an/a

-US$3m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$1mUS$590k

-US$7m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$1mUS$567k

-US$9m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$1mUS$545k

-US$11m

Sep 30 2018n/an/a

-US$6m

Jun 30 2018n/an/a

-US$5m

Mar 31 2018n/an/a

-US$9m

Dec 31 2017US$1mUS$523k

-US$8m

Compensation vs Market: A.'s total compensation ($USD1.17M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: A.'s compensation has been consistent with company performance over the past year.

CEO

A. Kazimi (66 yo)

25.9yrs

Tenure

US$1,169,530

Compensation

Mr. A. J. Kazimi, MBA, founded Cumberland Pharmaceuticals Inc. in 1999 and has been its Chairman and Chief Executive Officer since 1999. Mr. Kazimi serves as the President of Cumberland Pharmaceuticals Inc...

Leadership Team

NamePositionTenureCompensationOwnership
A. Kazimi
Founder25.9yrsUS$1.17m40.6%
$ 12.9m
John Hamm
VP & CFO3.6yrsUS$282.32k0.19%
$ 59.0k
James Herman
Executive VP of National Accounts & Chief Compliance Officer8.2yrsUS$400.15k0.27%
$ 86.8k
Chris Bitterman
Vice President of Sales & Marketingno dataUS$316.29k0.033%
$ 10.6k
Todd Anthony
Vice President of Organizational Developmentno dataUS$330.85k0.12%
$ 37.1k
Jean Marstiller
Senior VP of Administrative Services & Corporate Secretaryno dataUS$298.01kno data
Adam Mostafa
Managing Director5.8yrsno datano data
Erin Gull
Senior Corporate Relations Associateno datano datano data

7.0yrs

Average Tenure

66yo

Average Age

Experienced Management: CPIX's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
A. Kazimi
Founder25.9yrsUS$1.17m40.6%
$ 12.9m
Joseph Williams
Member of Pharmaceutical Advisory Boardno datano datano data
Joseph Galante
Independent Director6.3yrsUS$61.20k0.42%
$ 134.7k
Robert Roberts
Member of Medical Advisory Boardno datano datano data
Gordon Bernard
Chairman of Medical Advisory Board & Independent Director14.9yrsUS$98.00kno data
J. Hix
Member of Pharmaceutical Advisory Boardno dataUS$233.65kno data
Martin Brown
Director2.4yrsUS$50.00k0.043%
$ 13.6k
David Warrell
Member of Medical Advisory Boardno datano datano data
Timothy Meakin
Member of Pharmaceutical Advisory Boardno datano datano data
Ben deBoisblanc
Member of Medical Advisory Boardno datano datano data
Caroline Young
Independent Director8.3yrsUS$61.20k0.21%
$ 67.3k
James Jones
Independent Director14.9yrsUS$60.20kno data

11.6yrs

Average Tenure

72yo

Average Age

Experienced Board: CPIX's board of directors are seasoned and experienced ( 11.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:10
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cumberland Pharmaceuticals Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Irina Rivkind KofflerDuncan-Williams, Inc.
David WindleyJefferies LLC